Wex Pharmaceuticals Inc.

Wex Pharmaceuticals Inc.

International Wex Technologies Inc. (the 'Company') is a neuro-
bioscience company, federally incorporated in Canada in
1992, dedicated to the discovery of medicine for the management
of pain in order to minimize human suffering. The Company is a
leader in the extraction, refinement and manufacture of
Tetrodotoxin (TTX), a purified complex, non-protein toxin
extracted from the puffer fish. The Company initially identified
TTX for use in the management of pain and other symptoms
associated with withdrawal from prescription and non-
prescription opiates, and used the trade name Tetrodin
for this indication. The Company also conducted research on the
analgesic effects of TTX in order to determine the potential
for the market for the management of chronic and acute pain.
The trade name Tectin is used for these potential analgesic
indications. In animal studies involving TTX, the potential of
the drug substance for use as a local or regional anesthetic
was also identified. The Company uses the trade name Tocudin
for these anesthetic indications.
Since the company's public listing on the Canadian Ventures
Exchange in 1992 to the present, substantial capital has
been directed to the research and development of various drugs,
and subsequently, the protection of our intellectual knowledge
by filing multiple patents. The lead products, Tetrodin and
Tectin are being processed through the regulatory channels for
approvals in Canada, United States and Europe, and ultimately
pharmaceutical sales.

Company Details

Year Established: 1992

Number of Employees: 12

Company Information

Donna Shum
Title: Chief Operating Officer
Telephone: (604) 683-8880
Fax: (604) 683-8868
Email: Click Here

Grace Leong
Title: Business Development Director
Telephone: (604) 683-8880
Fax: (604) 683-8868
Email: Click Here

Products

Tectin

Tetrodin
A revolutionary non-narcotic pharmaceutical, with potent analgesic properties, developed from the naturally organic substance tetrodotoxin (TTX). Tetrodin, with experiments to date, has shown to provide a safe, cost effective primary withdrawal treatment solution for heroin and other opiate addiction to substances such as morphine, opium and methadone.

Tocudin
Targeted at the local and topical anesthetic market, for patients undergoing surgery or procedures for which general anesthesia (loss of consciousness) may be impractical or unnecessary, Tocudin is undergoing intensive preclinical testing at the world-renowned Beijing Medical University in China, where the Company's research & development and manufacturing operations are currently located, resulting to date in positive and very promising results.

Services